Literature DB >> 22232667

T helper cell- and CD40-dependent germline IgM prevents chronic virus-induced demyelinating disease.

Cristina Gil-Cruz1, Christian Perez-Shibayama, Sonja Firner, Ari Waisman, Ingo Bechmann, Volker Thiel, Luisa Cervantes-Barragan, Burkhard Ludewig.   

Abstract

Generation of antiviral IgM is usually considered as a marker of a short-lived initial antibody response that is replaced by hypermutated and more-efficient IgG. However, once viruses have established a particular niche for their persistence (e.g., within the CNS), the immune system has to specifically mobilize a broad range of antimicrobial effectors to contain the pathogen in the long term. Infection of the CNS with the mouse hepatitis virus (MHV) provides a unique model situation in which the extent of inflammatory CNS disease is determined by the balance between antiviral immune control, viral replication, and immune-mediated damage. We show here that whereas antibody- or B cell-deficient mice failed to contain MHV CNS infection and developed progressive demyelinating disease, germline IgM produced in activation-induced cytidine deaminase-deficient mice (aicda(-/-)) provided long-term protection against the chronic multiple sclerosis-like disease. Furthermore, we found that appropriate B-cell activation within the CNS-draining lymph node and subsequent CXCR3-mediated migration of antiviral IgM-secreting cells to the infected CNS was dependent on CD40-mediated interaction of B cells with T helper cells. These data indicate that the CD40-mediated collaboration of T and B cells is critical to secure neuroprotective IgM responses during viral CNS infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22232667      PMCID: PMC3268283          DOI: 10.1073/pnas.1115154109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in a Sardinian population.

Authors:  Maura Pugliatti; Trond Riise; M Alessandra Sotgiu; Wanda M Satta; Stefano Sotgiu; M Immacolata Pirastru; Giulio Rosati
Journal:  Am J Epidemiol       Date:  2006-06-05       Impact factor: 4.897

2.  Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA.

Authors:  S S Soldan; R Berti; N Salem; P Secchiero; L Flamand; P A Calabresi; M B Brennan; H W Maloni; H F McFarland; H C Lin; M Patnaik; S Jacobson
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

Review 3.  B cells and multiple sclerosis.

Authors:  Diego Franciotta; Marco Salvetti; Francesco Lolli; Barbara Serafini; Francesca Aloisi
Journal:  Lancet Neurol       Date:  2008-09       Impact factor: 44.182

Review 4.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

Review 5.  New tools to study the role of B cells in cytomegalovirus infections.

Authors:  Ari Waisman; Andrew L Croxford; Filiz Demircik
Journal:  Med Microbiol Immunol       Date:  2008-03-11       Impact factor: 3.402

6.  Risk alleles for multiple sclerosis identified by a genomewide study.

Authors:  David A Hafler; Alastair Compston; Stephen Sawcer; Eric S Lander; Mark J Daly; Philip L De Jager; Paul I W de Bakker; Stacey B Gabriel; Daniel B Mirel; Adrian J Ivinson; Margaret A Pericak-Vance; Simon G Gregory; John D Rioux; Jacob L McCauley; Jonathan L Haines; Lisa F Barcellos; Bruce Cree; Jorge R Oksenberg; Stephen L Hauser
Journal:  N Engl J Med       Date:  2007-07-29       Impact factor: 91.245

7.  Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response.

Authors:  C Jacobi; P Lange; H Reiber
Journal:  J Neuroimmunol       Date:  2007-05-21       Impact factor: 3.478

8.  CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.

Authors:  A Oxenius; K A Campbell; C R Maliszewski; T Kishimoto; H Kikutani; H Hengartner; R M Zinkernagel; M F Bachmann
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

9.  Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines.

Authors:  Roland Züst; Luisa Cervantes-Barragán; Thomas Kuri; Gjon Blakqori; Friedemann Weber; Burkhard Ludewig; Volker Thiel
Journal:  PLoS Pathog       Date:  2007-08-10       Impact factor: 6.823

10.  Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients.

Authors:  Annie Boucher; Marc Desforges; Pierre Duquette; Pierre J Talbot
Journal:  Clin Immunol       Date:  2007-04-19       Impact factor: 3.969

View more
  12 in total

1.  Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Authors:  Stephanie A Planque; Yukie Mitsuda; Vida Chitsazzadeh; Santhi Gorantla; Larisa Poluektova; Yasuhiro Nishiyama; Christina Ochsenbauer; Mary-Kate Morris; Gopal Sapparapu; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

2.  Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis.

Authors:  Timothy W Phares; Stephen A Stohlman; David R Hinton; Cornelia C Bergmann
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

3.  Germ Line IgM Is Sufficient, but Not Required, for Antibody-Mediated Alphavirus Clearance from the Central Nervous System.

Authors:  Voraphoj Nilaratanakul; Jie Chen; Oanh Tran; Victoria K Baxter; Elizabeth M Troisi; Jane X Yeh; Diane E Griffin
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

5.  Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes.

Authors:  Jung Hwan Sung; Han Zhang; E Ashley Moseman; David Alvarez; Matteo Iannacone; Sarah E Henrickson; Juan C de la Torre; Joanna R Groom; Andrew D Luster; Ulrich H von Andrian
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

6.  Progression from IgD+ IgM+ to isotype-switched B cells is site specific during coronavirus-induced encephalomyelitis.

Authors:  Timothy W Phares; Krista D DiSano; Stephen A Stohlman; Cornelia C Bergmann
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

Review 7.  Intrathecal humoral immunity to encephalitic RNA viruses.

Authors:  Timothy W Phares; Stephen A Stohlman; Cornelia C Bergmann
Journal:  Viruses       Date:  2013-02-15       Impact factor: 5.048

8.  Analysis of the host transcriptome from demyelinating spinal cord of murine coronavirus-infected mice.

Authors:  Ruth Elliott; Fan Li; Isabelle Dragomir; Ming Ming W Chua; Brian D Gregory; Susan R Weiss
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

9.  Central Nervous System Stromal Cells Control Local CD8(+) T Cell Responses during Virus-Induced Neuroinflammation.

Authors:  Jovana Cupovic; Lucas Onder; Cristina Gil-Cruz; Elke Weiler; Sonja Caviezel-Firner; Christian Perez-Shibayama; Thomas Rülicke; Ingo Bechmann; Burkhard Ludewig
Journal:  Immunity       Date:  2016-02-23       Impact factor: 31.745

10.  Maturation of lymph node fibroblastic reticular cells from myofibroblastic precursors is critical for antiviral immunity.

Authors:  Qian Chai; Lucas Onder; Elke Scandella; Cristina Gil-Cruz; Christian Perez-Shibayama; Jovana Cupovic; Renzo Danuser; Tim Sparwasser; Sanjiv A Luther; Volker Thiel; Thomas Rülicke; Jens V Stein; Thomas Hehlgans; Burkhard Ludewig
Journal:  Immunity       Date:  2013-04-25       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.